Provided By GlobeNewswire
Last update: Feb 11, 2025
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that updated clinical data on resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) will be featured in presentations at the 2025 American Association for the Advancement of Science Annual Meeting, which is being held at the Hynes Convention Center in Boston, MA from February 13-15, 2025, and the 5th International Conference on Lymphocyte Engineering, which is being held at the Holiday Inn Munich – City Center in Munich, Germany from February 20-22, 2025. The presentations will include safety, translational data and clinical outcomes from the first 10 patients dosed with rese-cel across multiple ongoing clinical trials in the RESET™ clinical development program.
Read more at globenewswire.com1.57
-0.13 (-7.65%)
Find more stocks in the Stock Screener
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.